{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:04:51Z","timestamp":1789049091443,"version":"build-2803163510"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.phrs.2016.03.039","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T11:03:13Z","timestamp":1459681393000},"page":"333-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"special_numbering":"C","title":["mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis"],"prefix":"10.1016","volume":"107","author":[{"given":"Rita","family":"Citraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Constanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.03.039_bib0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/14737175.6.3.397","article-title":"Refractory epilepsy: mechanisms and solutions","volume":"6","author":"Kwan","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2016.03.039_bib0010","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1517\/14656566.2015.1084504","article-title":"Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis","volume":"16","author":"Palleria","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2016.03.039_bib0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/B978-0-444-52899-5.00025-3","article-title":"Pharmacoresistance","volume":"108","author":"Potschka","year":"2012","journal-title":"Handbook Clin. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13311-014-0257-2","article-title":"Past and present definitions of epileptogenesis and its biomarkers","volume":"11","author":"Pitkanen","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2016.03.039_bib0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13311-013-0250-1","article-title":"Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies","volume":"11","author":"White","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2016.03.039_bib0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/WCO.0000000000000067","article-title":"Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward","volume":"27","author":"Trinka","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fnmol.2014.00028","article-title":"Mtor signaling and its roles in normal and abnormal brain development","volume":"7","author":"Takei","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0040","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1152\/physrev.00038.2014","article-title":"Mtor in brain physiology and pathologies","volume":"95","author":"Bockaert","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2016.03.039_bib0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40263-014-0223-x","article-title":"Mtor inhibition in epilepsy: rationale and clinical perspectives","volume":"29","author":"Ostendorf","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2016.03.039_bib0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/2051-5960-2-71","article-title":"Evidence for mtor pathway activation in a spectrum of epilepsy-associated pathologies","volume":"2","author":"Liu","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.phrs.2016.03.039_bib0055","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12035-012-8314-5","article-title":"The mtor signaling pathway in the brain: focus on epilepsy and epileptogenesis","volume":"46","author":"Russo","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/2319-4170.110365","article-title":"Mammalian target of rapamycin (mtor) pathways in neurological diseases","volume":"36","author":"Wong","year":"2013","journal-title":"Biomed. J."},{"key":"10.1016\/j.phrs.2016.03.039_bib0065","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.molmed.2011.07.008","article-title":"Mtor: a pathogenic signaling pathway in developmental brain malformations","volume":"17","author":"Crino","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2016.03.039_bib0070","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022442","article-title":"Mtor signaling in epilepsy: insights from malformations of cortical development","volume":"5","author":"Crino","year":"2015","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"10.1016\/j.phrs.2016.03.039_bib0075","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/ern.13.49","article-title":"Mtor inhibitors as a new therapeutic option for epilepsy","volume":"13","author":"Curatolo","year":"2013","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2016.03.039_bib0080","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.pharep.2014.12.017","article-title":"Role of mtor inhibitors in epilepsy treatment","volume":"67","author":"Sadowski","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.phrs.2016.03.039_bib0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (exist-1): A multicentre randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2016.03.039_bib0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpn.2011.09.006","article-title":"Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex","volume":"16","author":"Perek-Polnik","year":"2012","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2011.10.002","article-title":"Mammalian target of rapamycin (mtor) activation in focal cortical dysplasia and related focal cortical malformations","volume":"244","author":"Wong","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0100","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1523\/JNEUROSCI.0066-09.2009","article-title":"The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy","volume":"29","author":"Zeng","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0105","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1523\/JNEUROSCI.4852-10.2011","article-title":"Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy","volume":"31","author":"Buckmaster","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neulet.2011.12.051","article-title":"Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy","volume":"509","author":"Sliwa","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2016.03.039_bib0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"Mtor: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drudis.2006.12.008","article-title":"Targeting mammalian target of rapamycin (mtor) for health and diseases","volume":"12","author":"Tsang","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2016.03.039_bib0125","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.cellsig.2013.03.017","article-title":"The rationale of targeting mammalian target of rapamycin for ischemic stroke","volume":"25","author":"Chong","year":"2013","journal-title":"Cell. Signalling"},{"key":"10.1016\/j.phrs.2016.03.039_bib0130","first-page":"895","article-title":"Mammalian target of rapamycin: master regulator of cell growth in the nervous system","volume":"22","author":"Sandsmark","year":"2007","journal-title":"Histol Histopathol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/glia.22433","article-title":"Mtor kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis","volume":"61","author":"Dello Russo","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0140","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1523\/JNEUROSCI.2270-05.2005","article-title":"Control of dendritic arborization by the phosphoinositide-3'-kinase-akt-mammalian target of rapamycin pathway","volume":"25","author":"Jaworski","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0145","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1523\/JNEUROSCI.2284-05.2005","article-title":"Regulation of dendritic morphogenesis by ras-pi3k-akt-mtor and ras-mapk signaling pathways","volume":"25","author":"Kumar","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5607\/en.2015.24.3.177","article-title":"Roles of mtor signaling in brain development","volume":"24","author":"Lee da","year":"2015","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0155","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.neuron.2012.08.002","article-title":"Excessive activation of mtor in postnatally generated granule cells is sufficient to cause epilepsy","volume":"75","author":"Pun","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2016.03.039_bib0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuroscience.2012.05.003","article-title":"Rapamycin down-regulates kcc2 expression and increases seizure susceptibility to convulsants in immature rats","volume":"219","author":"Huang","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2016.03.039_bib0165","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1126\/science.1131693","article-title":"Activity- and mtor-dependent suppression of kv1.1 channel mrna translation in dendrites","volume":"314","author":"Raab-Graham","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.03.039_bib0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ana.10648","article-title":"Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model","volume":"54","author":"Wong","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0175","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1038\/ncomms5563","article-title":"Selective suppression of excessive glun2c expression rescues early epilepsy in a tuberous sclerosis murine model","volume":"5","author":"Lozovaya","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2016.03.039_bib0180","article-title":"Targeting molecules to medicine with mtor, autophagy, and neurodegenerative disorders","author":"Maiese","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0185","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/nn.3546","article-title":"Mtor complexes in neurodevelopmental and neuropsychiatric disorders","volume":"16","author":"Costa-Mattioli","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lfs.2014.02.014","article-title":"The role of mtor in depression and antidepressant responses","volume":"101","author":"Abelaira","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0195","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.pnpbp.2011.05.010","article-title":"The mtor signaling pathway in the prefrontal cortex is compromised in major depressive disorder","volume":"35","author":"Jernigan","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2016.03.039_bib0200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.pnpbp.2012.08.001","article-title":"Reduced phosphorylation of the mtor signaling pathway components in the amygdala of rats exposed to chronic stress","volume":"40","author":"Chandran","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2016.03.039_bib0205","doi-asserted-by":"crossref","first-page":"e20198","DOI":"10.1371\/journal.pone.0020198","article-title":"Long-term continuous corticosterone treatment decreases vegf receptor-2 expression in frontal cortex","volume":"6","author":"Howell","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.03.039_bib0210","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"Mtor-dependent synapse formation underlies the rapid antidepressant effects of nmda antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.03.039_bib0215","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3892\/mmr.2013.1600","article-title":"Effects of ketamine on lipopolysaccharide-induced depressive-like behavior and the expression of inflammatory cytokines in the rat prefrontal cortex","volume":"8","author":"Yang","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2016.03.039_bib0220","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1523\/JNEUROSCI.3696-09.2010","article-title":"Dysregulation of mtor signaling in fragile x syndrome","volume":"30","author":"Sharma","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0225","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/NEN.0000000000000083","article-title":"Mtor hyperactivation in down syndrome hippocampus appears early during development","volume":"73","author":"Iyer","year":"2014","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0230","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/hmg\/ddq563","article-title":"Reduced akt\/mtor signaling and protein synthesis dysregulation in a rett syndrome animal model","volume":"20","author":"Ricciardi","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2016.03.039_bib0235","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1101\/lm.027664.112","article-title":"A recollection of mtor signaling in learning and memory","volume":"20","author":"Graber","year":"2013","journal-title":"Learn. Mem."},{"key":"10.1016\/j.phrs.2016.03.039_bib0240","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"Mtor signaling: at the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2016.03.039_bib0245","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1601-183X.2006.00224.x","article-title":"Dendritic pathology in mental retardation: from molecular genetics to neurobiology","volume":"5","author":"Dierssen","year":"2006","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.phrs.2016.03.039_bib0250","doi-asserted-by":"crossref","first-page":"12977","DOI":"10.1523\/JNEUROSCI.4209-06.2006","article-title":"Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons","volume":"26","author":"Parsons","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0255","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1073\/pnas.1014715108","article-title":"Selective pharmacogenetic inhibition of mammalian target of rapamycin complex i (mtorc1) blocks long-term synaptic plasticity and memory storage","volume":"108","author":"Stoica","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.03.039_bib0260","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1523\/JNEUROSCI.0671-06.2006","article-title":"Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex-mammalian target of rapamycin pathway","volume":"26","author":"Dash","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0265","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.neuron.2008.09.037","article-title":"Removal of fkbp12 enhances mtor-raptor interactions, ltp, memory, and perseverative\/repetitive behavior","volume":"60","author":"Hoeffer","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2016.03.039_bib0270","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1046\/j.1460-9568.2003.02820.x","article-title":"Rapamycin-sensitive signalling in long-term consolidation of auditory cortex-dependent memory","volume":"18","author":"Tischmeyer","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0275","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2788.2009.01208.x","article-title":"From mtor to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis","volume":"53","author":"Ehninger","year":"2009","journal-title":"J. Intellect. Disabil. Res."},{"key":"10.1016\/j.phrs.2016.03.039_bib0280","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a tsc2+\/\u2fff mouse model of tuberous sclerosis","volume":"14","author":"Ehninger","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2016.03.039_bib0285","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of mtor","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2016.03.039_bib0290","article-title":"New perspectives on the involvement of mtor in depression as well as in the action of antidepressant drugs","author":"Ignacio","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0295","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-61779-430-8_14","article-title":"Quantitative visualization of autophagy induction by mtor inhibitors","volume":"821","author":"Nyfeler","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","article-title":"Protein aggregates in huntington's disease","volume":"238","author":"Arrasate","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0305","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2119\/2007-00100.Irvine","article-title":"Protein aggregation in the brain: the molecular basis for alzheimer's and parkinson's diseases","volume":"14","author":"Irvine","year":"2008","journal-title":"Mol. Med."},{"key":"10.1016\/j.phrs.2016.03.039_bib0310","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mtor induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2016.03.039_bib0315","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/hmg\/ddi458","article-title":"Rapamycin alleviates toxicity of different aggregate-prone proteins","volume":"15","author":"Berger","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2016.03.039_bib0320","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2013.05.029","article-title":"Role of the mtor signaling pathway in epilepsy","volume":"332","author":"Meng","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0325","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neulet.2011.02.037","article-title":"Therapeutic role of mammalian target of rapamycin (mtor) inhibition in preventing epileptogenesis","volume":"497","author":"McDaniel","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2016.03.039_bib0330","series-title":"Jasper's Basic Mechanisms of the Epilepsies","article-title":"Mtor and epileptogenesis in developmental brain malformations","author":"Wong","year":"2012"},{"key":"10.1016\/j.phrs.2016.03.039_bib0335","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fnmol.2014.00018","article-title":"Mechanisms regulating neuronal excitability and seizure development following mtor pathway hyperactivation","volume":"7","author":"Lasarge","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0340","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1528-1167.2012.03506.x","article-title":"Finding a better drug for epilepsy: the mtor pathway as an antiepileptogenic target","volume":"53","author":"Galanopoulou","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0345","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nbd.2006.12.003","article-title":"Rapamycin is a neuroprotective treatment for traumatic brain injury","volume":"26","author":"Erlich","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2016.03.039_bib0350","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.nbd.2011.03.021","article-title":"A pulse rapamycin therapy for infantile spasms and associated cognitive decline","volume":"43","author":"Raffo","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2016.03.039_bib0355","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4161\/auto.6.3.11261","article-title":"Activation of autophagy and akt\/creb signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia","volume":"6","author":"Carloni","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.phrs.2016.03.039_bib0360","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1528-1167.2007.01035.x","article-title":"Tuberous sclerosis complex and epilepsy: recent developments and future challenges","volume":"48","author":"Holmes","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0365","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/B978-0-444-52891-9.00038-5","article-title":"Tuberous sclerosis","volume":"111","author":"Curatolo","year":"2013","journal-title":"Handbook Clin. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0370","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.03.039_bib0375","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2014.10.028","article-title":"Mechanistic target of rapamycin (mtor) in tuberous sclerosis complex-associated epilepsy","volume":"52","author":"Curatolo","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0380","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s11940-013-0249-2","article-title":"Management of cns-related disease manifestations in patients with tuberous sclerosis complex","volume":"15","author":"Krueger","year":"2013","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0385","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1167.2009.02341.x","article-title":"Mammalian target of rapamycin (mtor) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies","volume":"51","author":"Wong","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0390","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1523\/JNEUROSCI.5540-06.2007","article-title":"A mouse model of tuberous sclerosis: neuronal loss of tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival","volume":"27","author":"Meikle","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0395","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI44909","article-title":"Single-cell tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice","volume":"121","author":"Feliciano","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2016.03.039_bib0400","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijdevneu.2013.02.008","article-title":"A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits","volume":"31","author":"Feliciano","year":"2013","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0405","article-title":"A tuber-ful animal model of tuberous sclerosis at last?","volume":"1","author":"Wong","year":"2012","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.phrs.2016.03.039_bib0410","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/glia.20036","article-title":"Loss of tuberous sclerosis complex 1 (tsc1) expression results in increased rheb\/s6k pathway signaling important for astrocyte cell size regulation","volume":"47","author":"Uhlmann","year":"2004","journal-title":"Glia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0415","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the mtor inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0420","article-title":"Systemic effects of treatment with mtor inhibitors in tuberous sclerosis complex: a comprehensive review","author":"Sadowski","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0425","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0430","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mtor) inhibitors: effects on mtorc1 and akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0435","doi-asserted-by":"crossref","first-page":"E1070","DOI":"10.1073\/pnas.1106454108","article-title":"Regulable neural progenitor-specific tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex","volume":"108","author":"Goto","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.03.039_bib0440","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/hmg\/ddq491","article-title":"Tsc2 gene inactivation causes a more severe epilepsy phenotype than tsc1 inactivation in a mouse model of tuberous sclerosis complex","volume":"20","author":"Zeng","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2016.03.039_bib0445","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nbd.2015.04.016","article-title":"Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex","volume":"80","author":"Zhang","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2016.03.039_bib0450","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.23943","article-title":"Torc1-dependent epilepsy caused by acute biallelic tsc1 deletion in adult mice","volume":"74","author":"Abs","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0455","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yebeh.2012.12.033","article-title":"Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex","volume":"27","author":"Friedman","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.03.039_bib0460","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"Jozwiak","year":"2011","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0465","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpn.2009.03.003","article-title":"Early control of seizures improves long-term outcome in children with tuberous sclerosis complex","volume":"14","author":"Bombardieri","year":"2010","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0470","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: correcting misperceptions","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.phrs.2016.03.039_bib0475","doi-asserted-by":"crossref","first-page":"e57445","DOI":"10.1371\/journal.pone.0057445","article-title":"Vigabatrin inhibits seizures and mtor pathway activation in a mouse model of tuberous sclerosis complex","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.03.039_bib0480","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ng782","article-title":"Deletion of pten in mouse brain causes seizures, ataxia and defects in soma size resembling lhermitte-duclos disease","volume":"29","author":"Backman","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2016.03.039_bib0485","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00401-010-0714-x","article-title":"Focal cortical dysplasias: clinical implication of neuropathological classification systems","volume":"120","author":"Spreafico","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0490","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/epi.12876","article-title":"Long-term seizure outcome in 211 patients with focal cortical dysplasia","volume":"56","author":"Fauser","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0495","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3824","article-title":"Brain somatic mutations in mtor cause focal cortical dysplasia type ii leading to intractable epilepsy","author":"Lim","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2016.03.039_bib0500","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eplepsyres.2014.01.005","article-title":"Mirna expression analysis in cortical dysplasia: regulation of mtor and lis1 pathway","volume":"108","author":"Lee","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.phrs.2016.03.039_bib0505","doi-asserted-by":"crossref","first-page":"12923","DOI":"10.1073\/pnas.2132711100","article-title":"Mtor is required for hypertrophy of pten-deficient neuronal soma in vivo","volume":"100","author":"Kwon","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.03.039_bib0510","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1242\/dmm.002386","article-title":"Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia","volume":"2","author":"Ljungberg","year":"2009","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.phrs.2016.03.039_bib0515","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/epi.12946","article-title":"Mtor inhibition suppresses established epilepsy in a mouse model of cortical dysplasia","volume":"56","author":"Nguyen","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0520","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/j.1528-1167.2011.03280.x","article-title":"Inhibition of the mammalian target of rapamycin blocks epilepsy progression in ns-pten conditional knockout mice","volume":"52","author":"Sunnen","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0525","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1523\/JNEUROSCI.5685-08.2009","article-title":"Pharmacological inhibition of mtorc1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific pten knock-out mice","volume":"29","author":"Zhou","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0530","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0079-6123(07)63029-5","article-title":"Unmasking recurrent excitation generated by mossy fiber sprouting in the epileptic dentate gyrus: an emergent property of a complex system","volume":"163","author":"Sutula","year":"2007","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.phrs.2016.03.039_bib0535","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1523\/JNEUROSCI.4179-08.2009","article-title":"Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy","volume":"29","author":"Buckmaster","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0540","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2010.05.024","article-title":"Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy","volume":"40","author":"Huang","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2016.03.039_bib0545","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1111\/j.1528-1167.2011.03253.x","article-title":"Rapamycin suppresses axon sprouting by somatostatin interneurons in a mouse model of temporal lobe epilepsy","volume":"52","author":"Buckmaster","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0550","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/epi.12246","article-title":"High-dose rapamycin blocks mossy fiber sprouting but not seizures in a mouse model of temporal lobe epilepsy","volume":"54","author":"Heng","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0555","doi-asserted-by":"crossref","first-page":"e64455","DOI":"10.1371\/journal.pone.0064455","article-title":"Spatiotemporal characterization of mtor kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment","volume":"8","author":"Macias","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.03.039_bib0560","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4255\/mcpharmacol.09.16","article-title":"Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of rapamycin (mtor) pathway","volume":"1","author":"Zeng","year":"2009","journal-title":"Mol. Cell. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2016.03.015","article-title":"Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain","author":"Hester","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0570","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bbrc.2012.02.143","article-title":"Rapamycin suppresses the recurrent excitatory circuits of dentate gyrus in a mouse model of temporal lobe epilepsy","volume":"420","author":"Tang","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2016.03.039_bib0575","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1528-1167.2012.03674.x","article-title":"Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide y expression in rats","volume":"53","author":"Chachua","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0580","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.phrs.2004.03.007","article-title":"Mtor: a protein kinase switching between life and death","volume":"50","author":"Asnaghi","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.03.039_bib0585","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.4161\/cc.9.12.11866","article-title":"Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mtor): a double-edged sword?","volume":"9","author":"Zeng","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.phrs.2016.03.039_bib0590","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1528-1167.2012.03513.x","article-title":"Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation","volume":"53","author":"van Vliet","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0595","article-title":"Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats i: magnetic resonance imaging","author":"van Vliet","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0600","article-title":"Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats ii: potential mechanisms","author":"van Vliet","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0605","article-title":"Deletion of mtor in reactive astrocytes suppresses chronic seizures in a mouse model of temporal lobe epilepsy","author":"Wang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0610","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuropharm.2012.09.019","article-title":"Mtor inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy","volume":"69","author":"Russo","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2016.03.039_bib0615","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-444-52898-8.00004-5","article-title":"Animal models","volume":"107","author":"Coppola","year":"2012","journal-title":"Handbook Clin. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0620","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bph.13121","article-title":"Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the wag\/rij rat model of absence epilepsy","volume":"172","author":"Citraro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0625","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbr.2011.07.030","article-title":"Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity","volume":"225","author":"Russo","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2016.03.039_bib0630","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s10072-014-1842-1","article-title":"The mtor signaling pathway and neuronal stem\/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model","volume":"35","author":"Russo","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2014.06.016","article-title":"Early molecular and behavioral response to lipopolysaccharide in the wag\/rij rat model of absence epilepsy and depressive-like behavior, involves interplay between ampk, akt\/mtor pathways and neuroinflammatory cytokine release","author":"Russo","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.phrs.2016.03.039_bib0640","doi-asserted-by":"crossref","first-page":"e35885","DOI":"10.1371\/journal.pone.0035885","article-title":"The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mtor) pathway","volume":"7","author":"Talos","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.03.039_bib0645","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1528-1167.2011.03220.x","article-title":"Validation of the rat model of cryptogenic infantile spasms","volume":"52","author":"Chachua","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.039_bib0650","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2011.02.033","article-title":"Anti-epileptogenesis in rodent post-traumatic epilepsy models","volume":"497","author":"Pitkanen","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2016.03.039_bib0655","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.drudis.2012.04.010","article-title":"Targeting mtor as a novel therapeutic strategy for traumatic cns injuries","volume":"17","author":"Don","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2016.03.039_bib0660","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/jcbfm.2014.113","article-title":"Role of akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice","volume":"34","author":"Zhu","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.phrs.2016.03.039_bib0665","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/jcbfm.2011.131","article-title":"Combination therapy targeting akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice","volume":"32","author":"Park","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.phrs.2016.03.039_bib0670","doi-asserted-by":"crossref","first-page":"e64078","DOI":"10.1371\/journal.pone.0064078","article-title":"Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury","volume":"8","author":"Guo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.03.039_bib0675","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ana.20949","article-title":"Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia","volume":"60","author":"Ljungberg","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0680","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1523\/JNEUROSCI.3870-12.2013","article-title":"Pi3k-akt signaling activates mtor-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy","volume":"33","author":"Berdichevsky","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.039_bib0685","doi-asserted-by":"crossref","first-page":"e45156","DOI":"10.1371\/journal.pone.0045156","article-title":"The mtor inhibitor rapamycin has limited acute anticonvulsant effects in mice","volume":"7","author":"Hartman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.03.039_bib0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2016.02.013","article-title":"Challenges in the pharmacological management of epilepsy and its causes in the elderly","author":"Ferlazzo","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.03.039_bib0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2016.03.016","article-title":"The challenges of treating epilepsy with 25 antiepileptic drugs","author":"Santulli","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.03.039_bib0700","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ebcr.2013.06.004","article-title":"Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior","volume":"1","author":"Gipson","year":"2013","journal-title":"Epilepsy Behav. Case Rep."},{"key":"10.1016\/j.phrs.2016.03.039_bib0705","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0710","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0715","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0720","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0725","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/11207730-000000000-00000","article-title":"Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"14","author":"Curran","year":"2012","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.phrs.2016.03.039_bib0730","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J. Pediatr."},{"key":"10.1016\/j.phrs.2016.03.039_bib0735","first-page":"129","article-title":"Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report","volume":"45","author":"Wiemer-Kruel","year":"2014","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.phrs.2016.03.039_bib0740","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejpn.2013.12.006","article-title":"Eeg abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients\u2fffa prospective study of 5 patients","volume":"18","author":"Domanska-Pakiela","year":"2014","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.phrs.2016.03.039_bib0745","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ebcr.2015.06.008","article-title":"Use of the mtor inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy","volume":"4","author":"Wheless","year":"2015","journal-title":"Epilepsy Behav. Case Rep."},{"key":"10.1016\/j.phrs.2016.03.039_bib0750","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12439","article-title":"De novo mutations in epileptic encephalopathies","volume":"501","author":"Allen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.03.039_bib0755","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.2329","article-title":"De novo somatic mutations in components of the pi3k-akt3-mtor pathway cause hemimegalencephaly","volume":"44","author":"Lee","year":"2012","journal-title":"Nat. Genet."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816302559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816302559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T14:57:25Z","timestamp":1536850645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816302559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":151,"alternative-id":["S1043661816302559"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.03.039","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}